Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.
about
Role of Statistical Random-Effects Linear Models in Personalized MedicineCovariate pharmacokinetic model building in oncology and its potential clinical relevance.Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyModeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in CatsZalcitabine population pharmacokinetics: application of radioimmunoassay.Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatientsA novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) modelsFever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokineticsDrug dosage individualization based on a random-effects linear model.Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphanThe prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance.Population pharmacokinetics: theory and practice.Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling timesComparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patientsThe accuracy of a pharmacokinetic theophylline predictor using once daily dosingAssociation between vancomycin trough concentration and area under the concentration-time curve in neonatesBayesian inference for generalized linear mixed model based on the multivariate t distribution in population pharmacokinetic studyKetorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months.Dose response relation to oral theophylline in severe chronic obstructive airways diseasePredictive Performance of a Vancomycin Population Pharmacokinetic Model in NeonatesPopulation pharmacokinetics I: background, concepts, and models.Population pharmacokinetics II: estimation methods.Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.Dynamic selection of models for a ventilator-management advisor.Sparse data analysis.Multiple imputation of missing covariates in NONMEM and evaluation of the method's sensitivity to η-shrinkage.Opportunities for model-based precision dosing in the treatment of sickle cell anemia.Clinical Decision Support Tools: The Evolution of a Revolution.Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.A Note on Recurring Misconceptions When Fitting Nonlinear Mixed Models.Quantifying pain relief following administration of a novel formulation of paracetamol (acetaminophen).A Bayesian dose-individualization method for warfarin.Population pharmacokinetics.Development of a bayesian forecasting method for warfarin dose individualization.Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century.Sources of prediction error when using a Bayesian method to evaluate nortriptyline serum concentrations.Predictive performance of the Bayesian analysis: effects of blood sampling time, population parameters, and pharmacostatistical model.Theophylline Population Pharmacokinetics and Dosing in Children Following Congenital Heart Surgery With Cardiopulmonary Bypass.Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing
P2860
Q24617125-75C6CDF7-B53C-4787-89F6-96998844242AQ27687599-BE0F0178-6A1B-4047-BA2E-069D13919181Q30443910-D86CEABB-2E7A-4CBD-B828-7562F61D2210Q31138427-9495D34F-7F91-4976-825D-7F7C34C69819Q33690050-63FD5AA0-5061-4BF1-BF2A-0590303139C7Q33692547-C5BCA9D9-7C42-4971-B4A3-99DB429C129AQ33692989-66E0EF9D-BB8A-4F82-BBAB-6D81E4B93340Q33751758-BFF6C1F7-9D14-41BC-80A2-AE47506A6860Q34261199-EE0A6548-033E-4D50-B116-F7449D838279Q34346859-7516F006-4823-4536-ABF1-21E1331F6E90Q34358674-86603CEC-C5AA-49F8-8047-A6B15463D001Q34358724-2613D79D-C155-4094-9196-18260DF9AAB8Q34397240-191BF60D-E336-4025-9B4E-507C45E078DEQ34397816-6F60FB72-375C-4800-AEBF-4C0818534D8EQ34416820-21EEFA14-A191-4DE3-9745-551A79496A4BQ34596435-E6D5EACD-5403-46F6-98EF-C87A5D20DDA7Q34631787-506F28B5-91C6-467C-8AE0-6A4F00272595Q34808175-7474BDFA-D4B0-42DB-9A20-884B67240995Q35706448-A7EE93F4-6AC3-4E3D-A179-CFA4BB3DC01DQ35752756-8E1257FB-F938-43FF-8092-379C196377C6Q35870696-108CE59A-EAE3-4019-8EBA-F8A4FDF04215Q35887615-66562CA5-E61E-4A58-9D4F-01087129DD62Q36054968-DA84F443-64C6-4D0F-945F-18C91E19F19AQ36470994-CDBC8F8E-C53A-438F-9F43-1EEFC2EFC09DQ36765409-5B1B0210-6DEA-4A2F-915D-8AA809853360Q37207747-D39A5177-5964-4463-A9C1-6EC0FB10ACCDQ38642609-DD3BA6C7-E999-4742-8B63-FDAEDA929CA9Q38702792-822BCFA4-2A79-4D22-9104-3693A6864F90Q39097052-1CC7F832-E965-4366-868A-2E8A8AF04F97Q39196494-880235EE-D6F6-47AA-80D9-AFC36C33A2E7Q39291089-C366DC90-0D6C-445B-82EB-E5B308DD710DQ39483373-08351C86-C3DD-4C25-A5D5-715B69D0DA11Q39571946-328536D9-7A26-486B-A109-C09F5E353C91Q39785314-4320CD54-4846-4BDC-9F4F-EBD322A31598Q40118820-3046A607-7452-4273-9270-0C43CC91FE84Q40749507-CF3410FD-C891-462D-8F4F-E791B35DBD8FQ41024547-EC18F9E5-7D28-477F-970B-CF0A1941B3DEQ41045157-E00FDE51-ABCF-4A55-B15E-D57DCC717C91Q41847013-D4627BBC-5952-4D3F-A307-1ADB9A238784Q41902015-17BCB4F3-97A0-47D6-BA62-ED838DEBA65C
P2860
Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh-hant
name
Bayesian individualization of ...... son with non-Bayesian methods.
@en
Bayesian individualization of ...... son with non-Bayesian methods.
@nl
type
label
Bayesian individualization of ...... son with non-Bayesian methods.
@en
Bayesian individualization of ...... son with non-Bayesian methods.
@nl
prefLabel
Bayesian individualization of ...... son with non-Bayesian methods.
@en
Bayesian individualization of ...... son with non-Bayesian methods.
@nl
P356
P1476
Bayesian individualization of ...... son with non-Bayesian methods.
@en
P2093
P304
P356
10.1002/JPS.2600711209
P407
P577
1982-12-01T00:00:00Z